NewAmsterdam Pharma Misses Earnings, Revenue Plummets 81%

NewAmsterdam Pharma (NAMS), ranking by market capitalization reported its fiscal 2026 Q2 earnings on Aug 06th, 2026. The company reported an EPS loss of $0.52, missing the consensus estimate of a $0.48 loss, while revenue of $3.70 million significantly trailed the forecast of $1.66 million. Management provided no specific quantitative guidance for the remainder of 2026, citing a focus on clinical milestones rather than immediate profitability targets.

Revenue

The total revenue of NewAmsterdam Pharma decreased by 80.7% to $3.70 million in 2026 Q2, down from $19.14 million in 2025 Q2, with specific segment revenue listed as follow: Supply revenue: $3.70 million and Total revenue: $3.70 million.

Earnings/Net Income

NewAmsterdam Pharma's losses deepened to $0.52 per share in 2026 Q2 from a loss of $0.15 per share in 2025 Q2 (246.7% wider loss). Meanwhile, the company's net loss widened to $-64.14 million in 2026 Q2, representing a 269.4% increase from the $-17.36 million loss recorded in 2025 Q2. The Company has sustained losses for 4 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The reported EPS miss and substantial revenue shortfall indicate deteriorating near-term financial health and execution challenges.

Price Action

The stock price of NewAmsterdam Pharma has edged up 0.33% during the latest trading day, has edged down 1.76% during the most recent full trading week, and has plummeted 21.43% month-to-date.

Post-Earnings Price Action Review

NewAmsterdam Pharma shares have exhibited significant volatility, losing approximately 21.5% year-to-date compared to the S&P 500’s 13% gain. Following the recent earnings release, which featured a notable miss on both earnings and revenue, the stock’s immediate trajectory remains sensitive to management’s commentary on the sustainability of current burn rates and the timeline for achieving commercial readiness. Investors are closely monitoring earnings estimate revisions, as empirical research suggests a strong correlation between these revisions and near-term price movements, particularly given the company’s history of underperforming consensus estimates over the last four quarters.

CEO Commentary

The Chief Executive Officer highlighted NewAmsterdam Pharma’s strategic focus on advancing its pipeline through key development milestones and fostering collaborative partnerships to accelerate commercialization efforts. Despite reporting a net loss of $64.14 million and an EPS of -$0.52 for the second quarter of 2026, with revenue reaching $3.70 million, leadership emphasized that current financial results reflect ongoing investments in clinical trials and operational scaling rather than immediate profitability concerns. The CEO maintained a cautiously optimistic tone, asserting that the company remains committed to its long-term growth trajectory and is well-positioned to capitalize on emerging opportunities within the pharmaceutical sector. Emphasis was placed on disciplined capital allocation and maintaining strong relationships with stakeholders to support sustainable value creation over time.

Guidance

For the remainder of 2026, NewAmsterdam Pharma does not provide specific quantitative guidance for revenue, EPS, or CAPEX in this report. However, qualitative expectations indicate continued focus on completing key clinical study endpoints and securing strategic partnerships to drive future revenue growth. The company anticipates maintaining its current burn rate while prioritizing efficient execution of its development timeline. Leadership expects to update investors on progress toward commercial readiness and potential milestones in subsequent earnings releases, reinforcing a commitment to transparency and disciplined financial management amid ongoing operational investments.

Additional News

NewAmsterdam Pharma Company NV (NAMS) recently announced dividend-related developments on August 6, 2026, marking a notable event in its corporate financial history. The company reported an ex-dividend date and associated payment details, which attracted attention from income-focused investors tracking yield metrics. This dividend activity stands as a primary non-earnings news item, distinct from the operational struggles highlighted in the quarterly report. No major mergers, acquisitions, or executive leadership changes were reported in the immediate vicinity of this date. The dividend announcement provides a snapshot of the company’s capital distribution strategy amidst its ongoing clinical development phases. Investors are observing how these distributions align with the firm’s broader cash burn rate and long-term solvency goals, given the significant net losses incurred in recent quarters.